Zobrazeno 1 - 10
of 234
pro vyhledávání: '"Roberto Chiarle"'
Mechanistic patterns and clinical implications of oncogenic tyrosine kinase fusions in human cancers
Autor:
Taek-Chin Cheong, Ahram Jang, Qi Wang, Giulia C. Leonardi, Biagio Ricciuti, Joao V. Alessi, Alessandro Di Federico, Mark M. Awad, Maria K. Lehtinen, Marian H. Harris, Roberto Chiarle
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-19 (2024)
Abstract Tyrosine kinase (TK) fusions are frequently found in cancers, either as initiating events or as a mechanism of resistance to targeted therapy. Partner genes and exons in most TK fusions are followed typical recurrent patterns, but the underl
Externí odkaz:
https://doaj.org/article/f91a851ffb1747f5bdae9ea30cb198bb
Autor:
Elisa Bergaggio, Roberto Chiarle
Publikováno v:
Clinical and Translational Medicine, Vol 14, Iss 6, Pp n/a-n/a (2024)
Externí odkaz:
https://doaj.org/article/6c4355bbc3e24d8c8be61f70b06763ad
Autor:
Stefano Pileri, Valentina Tabanelli, Roberto Chiarle, Angelica Calleri, Federica Melle, Giovanna Motta, Maria Rosaria Sapienza, Elena Sabattini, Pier Luigi Zinzani, Enrico Derenzini
Publikováno v:
Hemato, Vol 4, Iss 3, Pp 196-206 (2023)
The concept of gray-zone lymphoma (GZL) has been progressively refined since its introduction in the literature in 1998. For several years, it was applied to a rather broad spectrum of conditions, posing the problem of the differential diagnosis betw
Externí odkaz:
https://doaj.org/article/f8db9eaae74f414eabd0f815345ebeac
Autor:
Roberto Chiarle, Chiara Ambrogio
Publikováno v:
Molecular Oncology, Vol 17, Iss 11, Pp 2215-2217 (2023)
The development of tailored therapies designed to specifically target driver oncogenes has initiated a revolutionary era in cancer biology. The availability of a growing number of selective inhibitors has generated novel experimental and clinical par
Externí odkaz:
https://doaj.org/article/a945cf58d1e04f59af4ddf23636df7be
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-16 (2023)
CRISPR-Cas tools have shown exceptional promise in genome engineering over the past decade. Here the authors review the development of CRISPR-Cas9/Cas12/Cas13 nucleases, DNA base editors, prime editors, and RNA base editors, as well as their editing
Externí odkaz:
https://doaj.org/article/16e66e3df33e458983e9384509fe50fa
Autor:
Yoshihisa Kobayashi, Geoffrey R. Oxnard, Elizabeth F. Cohen, Navin R. Mahadevan, Joao V. Alessi, Yin P. Hung, Arrien A. Bertram, David E. Heppner, Mauricio F. Ribeiro, Karina P. Sacardo, Rodrigo Saddi, Mariana P. Macedo, Rafael B. Blasco, Jiaqi Li, Kari J. Kurppa, Tom Nguyen, Emma Voligny, Guruprasad Ananda, Roberto Chiarle, Artur Katz, Michael Y. Tolstorukov, Lynette M. Sholl, Pasi A. Jänne
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-14 (2022)
Fusion genes have been proposed as a potential mechanism of resistance to EGFR tyrosine kinase inhibitors (TKIs) in lung cancer. Here, the authors identify gene fusions that are associated with resistance to EGFR TKIs in non-small cell lung cancers,
Externí odkaz:
https://doaj.org/article/0ceddd06c4bb4ffa905cd1128f416204
Autor:
Matteo Villa, Federica Malighetti, Mario Mauri, Geeta G Sharma, Cosimo Lobello, Hugo Larose, Alessandra Pirola, Silvia Bombelli, Nicoletta Cordani, Luca Massimino, Šárka Pospíšilová, Suzanne D. Turner, Giorgio Inghirami, Lisa Pagani, Lucrezia Criscuolo, Fulvio Magni, Roberto Perego, Fabio Pagni, Rocco Piazza, Roberto Chiarle, Carlo Gambacorti-Passerini, Luca Mologni
Publikováno v:
HemaSphere, Vol 7, p e4206968 (2023)
Externí odkaz:
https://doaj.org/article/57ce5fe60c654f75b7e0fbc49a80ff02
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-17 (2022)
The identification of events occurring at target sites is critical to determine the safety of CRISPRbased DNA editing tools. Here, the authors show that LINE-1 retrotranspositions can occur frequently at canonical CRISPR/Cas9 editing sites, but are r
Externí odkaz:
https://doaj.org/article/475fb6a4bb494f549c6452ac89c19a9d
Autor:
Giulia Mura, Elif Karaca Atabay, Matteo Menotti, Cinzia Martinengo, Chiara Ambrogio, Gloria Giacomello, Maddalena Arigoni, Martina Olivero, Raffaele A. Calogero, Roberto Chiarle, Claudia Voena
Publikováno v:
Frontiers in Oncology, Vol 12 (2023)
Anaplastic Large Cell Lymphoma (ALCL) is a subtype of non-Hodgkin lymphoma frequently driven by the chimeric tyrosine kinase NPM-ALK, generated by the t (2,5)(p23;q35) translocation. While ALK+ ALCL belongs to mature T cell lymphomas, loss of T cell
Externí odkaz:
https://doaj.org/article/317284211cdb4f5b928511d2e4a6a4d4
Autor:
Marcin Nicoś, PhD, Luuk Harbers, MSc, Enrico Patrucco, PhD, Maximilian Kramer-Drauberg, PhD, Xiaolu Zhang, PhD, Claudia Voena, PhD, Anna Kowalczyk, MD, PhD, Aleksandra Bożyk, PhD, Rafał Pęksa, MD, PhD, Bożena Jarosz, MD, PhD, Justyna Szumiło, MD, Michele Simonetti, PhD, Monika Żuk, PhD, Bartosz Wasąg, MD, Katarzyna Reszka, PhD, Renata Duchnowska, MD, Janusz Milanowski, MD, Roberto Chiarle, MD, Magda Bienko, PhD, Paweł Krawczyk, MD, Jacek Jassem, MD, Chiara Ambrogio, PhD, Nicola Crosetto, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 12, Pp 100435- (2022)
Introduction: Brain metastases (BM) severely affect the prognosis and quality of life of patients with NSCLC. Recently, molecularly targeted agents were found to have promising activity against BM in patients with NSCLC whose primary tumors carry “
Externí odkaz:
https://doaj.org/article/93978b32039848998a35af7844ee33cf